

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date: Friday, July 24, 2026
Time: 11:00 am Central Time
Location: Zoom Teleconference
Institution: Northwestern University, Chicago, IL
Principal Investigator: Reem Karmali, MD, MS
Protocol: Kite Pharma, Inc., KT-US-484-0136
NCT Number: NCT05605899
Meeting Type: Continuing Review of Protocol and Site
Title: An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)

1. Call to order:

The Meeting was called to order at 11:15 am Central Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Five voting members were present, including two local members unaffiliated with the institution. Also present were four Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 5 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair noted changes since the last review.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for axicabtagene ciloleucel, since it consists of autologous T cells modified by a gammaretroviral vector. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of axicabtagene ciloleucel locally**, provided all other criteria for study closure are met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Point of Discussion:

1. The Committee had no questions or concerns about the facilities and practices.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representatives.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5

NO: 0

ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 11:19 am Central Time.

15. Post-meeting notes: None.

Documents reviewed:

Agenda

Protocol, Amendment 3, dated 01-08-2024

Investigator's Brochure, Edition 16, dated 01-07-2026

Investigational Product Manual, Version 13.0, dated 05-29-2026

Research Modification Evaluation, Investigator's Brochure, Edition 16

Research Modification Evaluation, Investigational Product Manual, Version 12.0

Research Modification Evaluation, Investigational Product Manual, Version 13.0

Biological Risk Assessment and Summary, updated 06-03-2026

Site Map, Olson, 1st Floor, dated 01-23-2026

Site Map, Olson, 7th Floor, MCCT, Room 7-424, dated 02-27-2025

Site Map, Prentice, 16th Floor, dated 04-12-2024

Site Map, Feinberg and Olson Loading Docks, received 10-16-2018

Site Inspection Checklist, Cell Therapies, expires 03-05-2027, updated 07-01-2026

Photos, Olson Pavilion, MCCT, dated 06-05-2025

Photos, Olson Pavilion, Dosing, dated 05-01-2025

Photos, Prentice Hospital, dated 04-25-2025

Photos, Feinberg and Olson Loading Dock, dated 03-25-2026

Biohazard Sign, Dosing Areas, dated 07-13-2026

Biohazard Sign, Olson MCCT, dated 07-13-2026

SOP, Biosafety for Genetically Modified Human Cells, dated 06-15-2026

SOP Addendum, Biosafety for Autologous Cells, dated 07-13-2026

Training, Shipping Certification, expires 06-05-2027

CRRF, dated 05-04-2026

Prior Meeting Minutes, Continuing, dated 08-27-2025